FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
Arch Womens Ment Health
; 2024 Mar 13.
Article
en En
| MEDLINE
| ID: mdl-38478035
ABSTRACT
Women going through menopause frequently experience vasomotor symptoms such as hot flashes, night sweats, and sleep disturbances, significantly influencing their quality of life. Hormonal therapy has been demonstrated to be beneficial in treating VMS. However, due to specific restrictions, it is not recommended for every woman. Fezolinetant, a neurokinin 3 antagonist and non-hormonal treatment for severe to moderate VMS, functions by inhibiting neuronal impulses originating from the hypothalamic thermoregulatory center. Current Skylight 2 and 4 trials statistically demonstrate the safety and acceptability of fezolinetant, with relatively few adverse effects reported. Fezolinetant has been shown great potential for treating menopausal-related VMS, supporting its further advancement. However, further investigation is required to thoroughly evaluate its safety, effectiveness, and its impact on sleep patterns.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Arch Womens Ment Health
Asunto de la revista:
PSICOLOGIA
/
SAUDE DA MULHER
Año:
2024
Tipo del documento:
Article
País de afiliación:
Pakistán